Company Description
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States.
The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.
It also provides BIAKŌS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKŌS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKŌS Antimicrobial Skin and Wound Irrigation Solution.
In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product.
Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
| Country | United States |
| Founded | 1982 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 108 |
| CEO | Ronald Nixon |
Contact Details
Address: 1200 Summit Avenue, Suite 414 Fort Worth, Texas 76102 United States | |
| Phone | 817 529 2300 |
| Website | sanaramedtech.com |
Stock Details
| Ticker Symbol | SMTI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000714256 |
| CUSIP Number | 79957L100 |
| ISIN Number | US79957L1008 |
| Employer ID | 59-2220004 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Ronald T. Nixon | Executive Chairman and Chief Executive Officer |
| Michael D. McNeil | Chief Financial Officer and Corporate Secretary |
| Jacob A. Waldrop | Chief Operating Officer |
| Bill Fitzgerald | Chief Compliance Officer |
| Tricia Matteson | Vice President of Marketing |
| Tyler Palmer | Chief Corporate Development and Strategy Officer |
| Dr. Christopher A. Morrison FACHM, FAPWCA, FCCWS, M.D. | President of Telehealth Services |
| Dr. Rebecca Erin Mcmahon | President of Research and Development |
| Seth Yon | President of Commercial |
| Callon Nichols | Vice President of Corporate Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 12, 2024 | 8-K | Current Report |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Oct 8, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 7, 2024 | 8-K | Current Report |
| Sep 23, 2024 | 8-K | Current Report |
| Sep 11, 2024 | 8-K | Current Report |
| Aug 12, 2024 | 8-K | Current Report |
| Aug 12, 2024 | 10-Q | Quarterly Report |
| Jul 26, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 20, 2024 | 8-K | Current Report |